{"title":"Early temporal suppression of SPARC inhibits oxidative stress, inflammation, and fibrosis in the chronic phase after renal ischemia/reperfusion","authors":"Hiroe Toba , Denan Jin , Shinji Takai","doi":"10.1016/j.jphs.2025.07.003","DOIUrl":null,"url":null,"abstract":"<div><div>Acute kidney injury is associated with not only high morbidity in the acute phase but also the development of chronic kidney disease (CKD). Recently, we found that suppression of secreted protein acidic and rich in cysteine (SPARC) exhibits renoprotective effects in acute ischemia/reperfusion (I/R) injury. The present study investigated the hypothesis that temporal suppression of SPARC in the early stages of I/R-injury might lead to the prevention of renal injury in the chronic phase. The left renal pedicle of male BALB/c mice was occluded for 45 min after right uninephrectomy and subsequently reperfused for 28 days. Small interfering RNA (siRNA) targeting SPARC was injected intravenously 1 day before and 3 days after I/R. Histological assessment revealed that SPARC knockdown by siRNA attenuated tubular injury, tubulointerstitial fibrosis, and the overexpression of 4-hydroxynonenal, a marker of lipid peroxidation. I/R-induced overexpression of a major source of superoxide NADPH oxidase, tumor necrosis factor-α, and matrix metalloproteinase-9 was suppressed by siRNA targeting SPARC. Treatment with siRNA targeting SPARC reduced the expression of a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1), which colocalizes with SPARC. In conclusion, SPARC might be a potential therapeutic target for preventing CKD development following acute I/R injury.</div></div>","PeriodicalId":16786,"journal":{"name":"Journal of pharmacological sciences","volume":"159 2","pages":"Pages 57-63"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmacological sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1347861325000738","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Acute kidney injury is associated with not only high morbidity in the acute phase but also the development of chronic kidney disease (CKD). Recently, we found that suppression of secreted protein acidic and rich in cysteine (SPARC) exhibits renoprotective effects in acute ischemia/reperfusion (I/R) injury. The present study investigated the hypothesis that temporal suppression of SPARC in the early stages of I/R-injury might lead to the prevention of renal injury in the chronic phase. The left renal pedicle of male BALB/c mice was occluded for 45 min after right uninephrectomy and subsequently reperfused for 28 days. Small interfering RNA (siRNA) targeting SPARC was injected intravenously 1 day before and 3 days after I/R. Histological assessment revealed that SPARC knockdown by siRNA attenuated tubular injury, tubulointerstitial fibrosis, and the overexpression of 4-hydroxynonenal, a marker of lipid peroxidation. I/R-induced overexpression of a major source of superoxide NADPH oxidase, tumor necrosis factor-α, and matrix metalloproteinase-9 was suppressed by siRNA targeting SPARC. Treatment with siRNA targeting SPARC reduced the expression of a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1), which colocalizes with SPARC. In conclusion, SPARC might be a potential therapeutic target for preventing CKD development following acute I/R injury.
期刊介绍:
Journal of Pharmacological Sciences (JPS) is an international open access journal intended for the advancement of pharmacological sciences in the world. The Journal welcomes submissions in all fields of experimental and clinical pharmacology, including neuroscience, and biochemical, cellular, and molecular pharmacology for publication as Reviews, Full Papers or Short Communications. Short Communications are short research article intended to provide novel and exciting pharmacological findings. Manuscripts concerning descriptive case reports, pharmacokinetic and pharmacodynamic studies without pharmacological mechanism and dose-response determinations are not acceptable and will be rejected without peer review. The ethnopharmacological studies are also out of the scope of this journal. Furthermore, JPS does not publish work on the actions of biological extracts unknown chemical composition.